From the Guidelines
For a patient who cannot tolerate metoprolol, bisoprolol is often the next best beta-blocker option, typically starting at 2.5-10 mg once daily, as it is preferred in patients with HFrEF and has a similar cardioselective profile but with a different side effect profile that some patients may tolerate better 1. When considering alternatives to metoprolol, it's essential to evaluate the patient's original indication for metoprolol, whether it was for hypertension, heart failure, angina, arrhythmia, or post-myocardial infarction.
- The choice of alternative medication should be based on the patient's comorbidities and the nature of the intolerance to metoprolol, such as fatigue, bradycardia, bronchospasm, or other side effects.
- If beta-blockers as a class need to be avoided, other options like ACE inhibitors, ARBs, or calcium channel blockers may be considered, depending on the patient's specific therapeutic goals and conditions, as outlined in the 2022 AHA/ACC/HFSA guideline for the management of heart failure 2.
- For example, if the patient has heart failure with reduced ejection fraction (HFrEF), bisoprolol or carvedilol may be preferred, while for hypertension or angina, alternatives like amlodipine or diltiazem could be considered.
- Ultimately, the selection of an alternative medication should prioritize the patient's morbidity, mortality, and quality of life outcomes, taking into account the most recent and highest-quality evidence available, such as the 2018 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults 1.
From the Research
Alternatives to Metoprolol
If a patient cannot tolerate metoprolol, there are several alternative beta-blockers that can be considered.
- Bisoprolol: This medication has been shown to be effective in reducing mortality and hospitalization in patients with heart failure 3, 4, 5.
- Carvedilol: Similar to bisoprolol, carvedilol has been proven to reduce mortality and hospitalization in patients with heart failure 3, 4, 5.
- Nebivolol: Although there is limited evidence, nebivolol has been shown to be effective in reducing mortality and hospitalization in patients with heart failure 4, 5.
Considerations for Switching Beta-Blockers
When switching from metoprolol to an alternative beta-blocker, it is essential to consider the following:
- Dose equivalence: The dose of the new beta-blocker should be equivalent to the dose of metoprolol 6.
- Propensity scores: Patients should be matched based on their propensity scores for beta-blocker treatment 7.
- Individual patient characteristics: The choice of beta-blocker should be based on individual patient characteristics, such as the presence of comorbidities or side effects 6.
Efficacy of Alternative Beta-Blockers
Studies have shown that bisoprolol, carvedilol, and metoprolol succinate have similar effects on mortality in patients with heart failure 7.
- A study comparing bisoprolol, carvedilol, and metoprolol succinate found no significant difference in mortality between the three groups 7.
- Another study found that bisoprolol and carvedilol were associated with lower mortality compared to metoprolol succinate, but the difference was not significant in matched samples 7.